Buy Or Sell Opportunity • Aug 18
Now 20% undervalued Over the last 90 days, the stock has risen 6.1% to ₩2,010. The fair value is estimated to be ₩2,513, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Jul 27
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 18% to ₩1,933. The fair value is estimated to be ₩2,490, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Meanwhile, the company has become profitable. New Risk • Jun 23
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₩14.9b (US$9.68m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₩14.9b market cap, or US$9.68m). Minor Risk Profit margins are more than 30% lower than last year (0.1% net profit margin). Valuation Update With 7 Day Price Move • Mar 19
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to ₩2,450, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 41% over the past three years. Aankondiging • Mar 11
Jeonjinbio Co., Ltd., Annual General Meeting, Mar 24, 2026 Jeonjinbio Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 295, seongseogongdanbuk-ro, dalseo-gu, daegu South Korea Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩1,848, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 54% over the past three years. New Risk • Oct 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩24.9b market cap, or US$17.5m). Valuation Update With 7 Day Price Move • Jul 24
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩3,260, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 19% over the past three years. New Risk • Jun 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩30.9b market cap, or US$22.7m). Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩2,630, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 41% over the past three years. New Risk • May 23
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 25% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risk Market cap is less than US$100m (₩20.3b market cap, or US$14.8m). Aankondiging • Mar 06
Jeonjinbio Co., Ltd., Annual General Meeting, Mar 20, 2025 Jeonjinbio Co., Ltd., Annual General Meeting, Mar 20, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 295, seongseogongdanbuk-ro, dalseo-gu, daegu South Korea Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩2,885, the stock trades at a trailing P/E ratio of 26.7x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 48% over the past three years. New Risk • Dec 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩21.3b market cap, or US$14.5m). New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩24.5b market cap, or US$17.0m). Aankondiging • Jun 15
Dabin BNS Co., Ltd. cancelled the acquisition of 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun. Dabin BNS Co., Ltd. agreed to acquire 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun for KRW 22 billion on October 13, 2023. The transaction is expected to close on November 24, 2023. As on November 24, 2023, the transaction is expected to close on December 15, 2023. The transaction is expected to complete on March 28, 2024. The transaction is expected to complete on May 9, 2024. The transaction is expected to complete on May 30, 2024. As of May 30, 2024, the transaction is expected to close on June 5, 2024. The transaction is expected to complete on June 07, 2024. As of June 7, 2024, the transaction is expected to close on June 13, 2024.Dabin BNS Co., Ltd. cancelled the acquisition of 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun on June 13, 2024. New Risk • Jun 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩33.4b market cap, or US$24.4m). Reported Earnings • May 19
First quarter 2024 earnings released: ₩36.00 loss per share (vs ₩169 loss in 1Q 2023) First quarter 2024 results: ₩36.00 loss per share (improved from ₩169 loss in 1Q 2023). Revenue: ₩4.41b (up 84% from 1Q 2023). Net loss: ₩282.3m (loss narrowed 76% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 14% per year. Aankondiging • May 09
Jeonjinbio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.9987 million. Jeonjinbio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.9987 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 188,679
Price\Range: KRW 5300
Transaction Features: Subsequent Direct Listing New Risk • Oct 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.6b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (9.0% increase in shares outstanding). Market cap is less than US$100m (₩63.6b market cap, or US$46.8m). New Risk • Aug 30
New major risk - Revenue and earnings growth Earnings have declined by 0.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.6b free cash flow). Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (9.0% increase in shares outstanding). Market cap is less than US$100m (₩40.4b market cap, or US$30.5m). New Risk • Jul 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.4b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (₩37.0b market cap, or US$29.3m). Is New 90 Day High Low • Mar 07
New 90-day high: ₩12,700 The company is up 2.0% from its price of ₩12,500 on 07 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period. Is New 90 Day High Low • Dec 08
New 90-day low: ₩9,900 The company is down 9.0% from its price of ₩10,900 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. Reported Earnings • Nov 14
Third quarter 2020 earnings released: ₩120 loss per share The company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: ₩1.08b (up 8.9% from 3Q 2019). Net loss: ₩577.5m (loss narrowed 7.2% from 3Q 2019). Is New 90 Day High Low • Oct 08
New 90-day high: ₩15,300 The company is up 174% from its price of ₩5,580 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 29% over the same period. Is New 90 Day High Low • Sep 22
New 90-day high: ₩12,800 The company is up 163% from its price of ₩4,860 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period. Aankondiging • Jun 20
Jeonjinbio Co., Ltd. announced that it has received KRW 3.5 billion in funding from KB Securities Co., Ltd., Investment Arm On June 18, 2020, Jeonjinbio Co., Ltd. (KOSDAQ:A110020) closed the transaction. Aankondiging • Jun 18
Jeonjinbio Co., Ltd. announced that it expects to receive KRW 3.5 billion in funding from KB Securities Co., Ltd., Investment Arm and other investors Jeonjinbio Co., Ltd. (KOSDAQ:A110020) announced a private placement of 7th series unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 3,500,000,000 on June 16, 2020. The bonds have a coupon rate of 1% and maturity date of June 18, 2023. The bonds are convertible into 702,106 common shares representing 14.64% stake at a conversion price of KRW 4,985 and the conversion period of the bonds will start from June 18, 2021 and end on May 18, 2023. The transaction will include participation from KB Securities Co., Ltd., Investment Arm for KRW 2,000,000,000, Gicheol Oh for KRW 1,000,000,000, JooEun Seo for KRW 300,000,000 and Geun-bae Kim for KRW 200,000,000. The transaction has been approved by the board of directors of the company. The payment date and subscription date of the transaction is June 18, 2020. The bonds are subject to prohibition of exercise for 1 year and prohibition of division/merging. 
